UNSPSC 51286102: Hexedine

This classification denotes a topical anti-infective agent with the molecular formula C22H45N3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LRE2528Y9E, chemically known as 2,6-bis(2-ethylhexyl)-hexahydro-7a-methyl-1h-imidazo(1,5-c)imidazole but more generally known as hexedine, which bears US NIH Compound Identifier 22291. European Medicines Agency schedules Hexedine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08035MIG. The term HEXEDINE is an International Non-Proprietary Name.

HEXEDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: N12C(CN(C1)CC(CCCC)CC)(CN(C2)CC(CCCC)CC)C.

UNSPSC 51286102 Hexedine is a Commodity code that does not align with state and local procurement activity in the recent opportunities block. The code nominally covers a specific pharmaceutical active ingredient, but the recent state and local solicitations tagged to it are instead procuring naloxone (an opioid-reversal medication), generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing, direct-to-manufacturer prescription programs, and general medical and first aid supplies for emergency response. None of these opportunities involve hexedine procurement. Issuing bodies across the activities include a county health department (Seminole County, Florida), a state health and human services commission (Texas HHS), a city fire department (Tampa), and a multistate cooperative purchasing alliance (MMCAP, administered by Minnesota). The scope varies widely—from specific community health initiatives centered on naloxone and drug deactivation systems to broad pharmaceutical supply contracts serving multiple state and local entities through authorized wholesalers to exploratory market research on direct-to-manufacturer contracting models.

The recent opportunities do not support characterization of hexedine as an active buying code. Seminole County's IFB 60459723LAS solicits 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to Sanford, Florida (response due July 26, 2023); the City of Tampa's IFB 26P00145 seeks medical and first aid supplies for the Fire Department Rescue Division across 169 line items with an estimated contract value of $700,000 and response due March 13, 2026; and MMCAP's RFP S1070000015802 establishes multiple contracts for generic multi-source pharmaceuticals and OTC products distributed to state and local facilities across Minnesota and Oregon with proposals due March 26, 2026. The Texas HHS Commission issued RFI HHS0017013 in March 2026 to gather market intelligence on direct-to-manufacturer prescription fulfillment capabilities, indicating exploratory procurement activity rather than active buying. The code shows no direct demand signal for hexedine itself and warrants reassessment against the actual work being solicited.